| C39 | Strategies used in countries with successful mother-infant pair tracking | E-poster | PMTCT, including services for vulnerable populations |
| C39 | Prevention of mother-to-child transmission (PMTCT) of HIV outcomes in infants of women who received Option B+ care during pregnancy in routine healthcare settings | E-poster | PMTCT, including services for vulnerable populations |
| C39 | Determinants of HIV-free survival in the era of lifelong universal antiretroviral therapy (ART): pooled analysis of PEAWIL and IMPROVE studies, Lesotho | E-poster | PMTCT, including services for vulnerable populations |
| C39 | The importance of surveys to complement program data in informing modeled Mother to Child HIV transmission (MTCT) estimates and identifying and addressing hidden program gaps: a case study of Uganda | E-poster | PMTCT, including services for vulnerable populations |
| B59 | No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial | E-poster | Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
| B59 | Expected impact of malnutrition on first-line antiretroviral drug exposure in a global population of children in countries with highest child mortality: a quantitative modeling and simulation study | E-poster | Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
| B59 | Pharmacokinetics and safety of dispersible and immediate release FDC abacavir/dolutegravir/lamivudine in children with HIV weighing '¥14 kg: preliminary results from IMPAACT 2019 | E-poster | Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
| B59 | Pharmacokinetics, safety and acceptability of a single dose of abacavir/lamivudine/lopinavir/ritonavir (4-in-1) fixed-dose granule formulation in neonates: PETITE study | E-poster | Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
| B36 | Safety and pharmacokinetics of islatravir in study participants with severe renal insufficiency | E-poster | Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring |
| D83 | Patient and provider perspectives on a novel, low-threshold PrEP program for people who inject drugs and experience homelessness | On-demand oral abstract session | People who use drugs (including by injection) |